Opendata, web and dolomites

PolyVac SIGNED

Polysaccharide-based membrane for sublingual vaccination

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PolyVac project word cloud

Explore the words cloud of the PolyVac project. It provides you a very rough idea of what is the project "PolyVac" about.

permit    additionally    patch    efficient    administered    preclinical    advantages    multilayer    safety    needle    enzymes    removal    dendritic    storage    vaccine    antigen    immunotherapy    gastrointestinal    model    proof    once    bypass    introduces    threatening    membrane    translation    tract    diseases    mucosal    transmission    thin    presented    envisages    human    countries    reduce    issue    immunization    double    record    temporally    overcoming    acknowledged    innovative    immunoactive    antigens    fs    pathogen    life    oral    follow    route    ones    bioactive    risk    molecules    vaccinating    vaginal    penetration    intranasal    subunit    clinical    injected    immune    loaded    commercialisation    fluids    interesting    sublingual    advantage    chemotactic    deg    drawbacks    hiv    mice    presenting    proteins    monitoring    mucosa    free    vaccination    infants    interface    pioneering    administration    polyvac    specificity    overcome    components    children    cells       body    cytokine    fast    vaccines    attracted    final    compliance   

Project "PolyVac" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://lbti.ibcp.fr/
 Total cost 173˙076 €
 EC max contribution 173˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-07-07   to  2019-07-06

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 173˙076.00

Map

 Project objective

Vaccination has been acknowledged as one of the most effective methods against life-threatening diseases. Vaccines administered by the mucosal route (oral, vaginal…) present the advantage to be needle-free and reduce the risk of pathogen transmission. Among the existing mucosal vaccines, the sublingual ones are an interesting way of immunization since the sublingual mucosa is particularly thin and would allow easy penetration of antigens. Also, this administration allows to bypass the gastrointestinal tract, has better safety record than intranasal vaccines and have better compliance for vaccinating infants and children. Additionally, they have a fast removal by body fluids and enzymes. PolyVac introduces a pioneering system for controlled targeted delivery of bioactive molecules and, for the proof of concept envisages the development of a sublingual vaccine for HIV. This concept comprises the development of a free-standing (FS) multilayer membrane that will present the double specificity to be immunoactive and specifically target the immune cells. To achieve this end, the FS will be loaded with a model antigen for immunotherapy and a chemotactic cytokine to specifically target the antigen presenting cells. Once loaded with the proteins, the FS membrane will become a bioactive patch. This patch will permit to deliver subunit vaccine components both spatially and temporally as dendritic cells will be attracted at the sublingual mucosa/patch interface ensuring efficient immune responses. Preclinical studies will follow in mice, by monitoring their immune response, for clinical translation and commercialisation of the proposed technology. It is expected to have, as final product, an innovative sublingual patch for human immunotherapy that among the advantages presented above will also overcome one of the main drawbacks of injected vaccines that is the storage at around 4°C. Overcoming this issue they could be widely used for immunotherapy in the developing countries.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POLYVAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "POLYVAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

EGeoCC (2019)

Ethnic geography and civil conflict

Read More  

E-CLIPS (2019)

Effects of Cross-Linguistic Interactions on Perception of Speech

Read More